Evidence map›Paper›PMID 35099005›Full record

ArticleBiology open2022

Genetically inducible and reversible zebrafish model of systemic inflammation.

Kevin A Lanham, Megan L Nedden, Virginia E Wise, Michael R Taylor

Open access · goldAbstract read
In one paragraph

Article in Biology open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Inflammation in Development and Aging: Insights from the Zebrafish Model.International journal of molecular sciences · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kevin A LanhamPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0001-6406-0019
Megan L NeddenPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0002-7180-6453
Virginia E WisePharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0003-4364-6912
Michael R TaylorPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA.ORCID 0000-0003-0848-4620
University of Wisconsin–Madison · USPharmaceutical Product Development (United States) · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Regulation of CNS angiogenesis and barriergenesisR01NS116043 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI TAYLOR, MICHAEL ROBERT · 2020 to 2024
$1.8M
NCATS NIH HHS UL1 TR002373NINDS NIH HHS R01 NS116043
6 · The paper itself

Abstract

The inflammatory response is a vital defense mechanism against trauma and pathogen induced damage, but equally important is its appropriate resolution. In some instances of severe trauma or sustained infection, inappropriate and persistent activation of the immune response can occur, resulting in a dangerous systemic inflammatory response. Untreated, this systemic inflammatory response can lead to tissue damage, organ shutdown, and death. Replicating this condition in tractable model organisms can provide insight into the mechanisms involved in the induction, maintenance, and resolution of inflammation. To that end, we developed a non-invasive, inducible, and reversible model of systemic inflammation in zebrafish. Using the Gal4-EcR/UAS system activated by the ecdysone analog tebufenozide, we generated transgenic zebrafish that allow for chemically induced, ubiquitous secretion of the mature form of zebrafish interleukin-1β (Il-1βmat) in both larval and adult developmental stages. To ensure a robust immune response, we attached a strong signal peptide from the Gaussia princeps luciferase enzyme to promote active secretion of the cytokine. We observe a dose-dependent inflammatory response involving neutrophil expansion accompanied by tissue damage and reduced survival. Washout of tebufenozide permits inflammation resolution. We also establish the utility of this model for the identification of small molecule anti-inflammatory compounds by treatment with the immunosuppressant rapamycin. Taken together, these features make this model a valuable new tool that can aid in identifying potential new therapies while broadening our understanding of systemic inflammation, its impact on the immune system, and its resolution.

Indexed as

InflammationZebrafishAnimalsAnimals, Genetically ModifiedSystemic Inflammatory Response SyndromeZebrafish ProteinsZebrafish ProteinsGal4-EcR/UASInflammationInterleukin-1βNeutrophilTebufenozideZebrafish

Identifiers

PMID35099005
PMCPMC8918989
OpenAlexW4210283534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.